CPF-DD is an inhibitor of infection by human immunodeficiency virus and other enveloped viruses in vitro.
The initial step in the infection cycle of human immunodeficiency virus type 1 (HIV-1) involves binding of its surface glycoprotein gp 120 to the T lymphocyte CD4 antigen. CPF-DD is a low molecular weight inhibitor of HIV infectivity that inhibits gp 120 binding to CD4 in vitro (Finberg et al., Science 249, 287-291, 1990). We find, however, that the actions of CPF-DD are not limited to its ability to interfere with gp 120-CD4 binding; its predominant action is to remove the viral envelope from the underlying core. Subsequently the virions disintegrate. Most enveloped viruses tested were inhibited by CPF-DD, but the infectivity of noneneloped viruses was unaffected or only slightly reduced.
Moore
J P
JP
Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom.
Simpson
G
G
McKeating
J A
JA
Burakoff
S J
SJ
Schreiber
S L
SL
Weiss
R A
RA
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001593:Benzyl Compounds / Q000494:pharmacology*; D015704:CD4 Antigens / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004151:Dipeptides / Q000494:pharmacology*; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D066298:In Vitro Techniques; D016086:Lentivirus / Q000187:drug effects; D011485:Protein Binding / Q000187:drug effects; D012190:Retroviridae / Q000187:drug effects; D014771:Virion / Q000187:drug effects*
D000998:Antiviral Agents; D001593:Benzyl Compounds; D015704:CD4 Antigens; D004151:Dipeptides; D015699:HIV Envelope Protein gp120; C067667:N-carbomethoxycarbonyl-prolyl-phenylalanyl-benzyl ester